Wall Street Zen Upgrades Senti Biosciences (NASDAQ:SNTI) to Sell

Senti Biosciences (NASDAQ:SNTI) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

Several other research firms have also commented on SNTI. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a report on Wednesday, October 8th. Leerink Partnrs raised shares of Senti Biosciences to a “strong-buy” rating in a report on Friday, November 21st. Chardan Capital boosted their price objective on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Leerink Partners started coverage on Senti Biosciences in a research report on Friday, November 21st. They set an “outperform” rating and a $6.00 target price on the stock. Finally, HC Wainwright assumed coverage on Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Senti Biosciences Stock Down 7.4%

Shares of NASDAQ SNTI opened at $1.31 on Friday. Senti Biosciences has a twelve month low of $1.26 and a twelve month high of $5.88. The firm has a market cap of $34.44 million, a PE ratio of -0.39 and a beta of 2.08. The business has a fifty day simple moving average of $1.94 and a two-hundred day simple moving average of $1.93.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.10). On average, research analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.

Institutional Trading of Senti Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in SNTI. Heights Capital Management Inc. acquired a new stake in shares of Senti Biosciences in the 1st quarter worth $2,520,000. Nantahala Capital Management LLC acquired a new position in Senti Biosciences during the 1st quarter valued at about $2,984,000. Geode Capital Management LLC raised its stake in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after buying an additional 117,588 shares during the last quarter. Armistice Capital LLC purchased a new stake in Senti Biosciences in the second quarter valued at about $1,883,000. Finally, Citadel Advisors LLC acquired a new stake in Senti Biosciences in the third quarter worth about $117,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.